Allergan Specialty Therapeutics Inc.

The Irvine drug research and development company reported a third-quarter net loss of $16.9 million, or $5.16 a share, compared with last year’s quarterly loss of $15.1 million, or $4.62 a share. Revenue, consisting of interest and investment income, declined 56% to $565,000.